Hims & Hers Health, Inc. (NYSE:HIMS) stock tanked around 26% on Friday after the U.S. FDA announced that the shortage of semaglutide injection products has been resolved. Data by YCharts Semaglutide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback